Core Viewpoint - The company has approved the use of idle fundraising for cash management, allowing investment in safe, liquid principal-protected products up to a maximum of RMB 1.5 billion [2][11]. Group 1: Cash Management Overview - The company plans to use idle funds from its non-public stock issuance to invest in principal-protected financial products, enhancing the efficiency and returns of the raised funds while ensuring no impact on ongoing projects [4][9]. - The cash management will involve a maximum of RMB 800 million in a structured deposit product from Hangzhou Bank, with a term of 364 days [6][10]. Group 2: Financial Product Redemption - The company redeemed a structured deposit product from Hangzhou Bank worth RMB 50 million, receiving the principal and a return of RMB 585,900 on June 6, 2025 [3]. Group 3: Financial Situation and Impact - As of March 31, 2025, the company's cash reserves were RMB 1,874.59 million, with the cash management investment representing 4.27% of total cash, indicating minimal impact on financial health [11]. - The use of idle funds for cash management is expected to improve fund utilization efficiency and generate returns for shareholders without affecting the company's operational projects [11].

热景生物6月9日龙虎榜 6月9日热景生物（688068）收盘价161.15元，收盘上涨18.15%，全天换手率6.41%，振幅24.46%，成交 额9.02亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.79亿元， 其中，买入成交额为2.37亿 元，卖出成交额为1.42亿元，合计净买入9503.95万元。具体来看，今日上榜的前五大买入营业部中，有 3家机构专用席位现身，即买一、买四、买五，买入金额分别为8867.62万元、3117.17万元、2460.83万 元，营业部合计买入9260.57万元。卖出营业部中，有1家机构专用席位现身，即卖二，卖出金额分别为 3442.21万元，营业部合计卖出1.08亿元。买卖金额相抵，机构专用席位今日净买入该股1.10亿元。 资金流向方面，该股今日全天主力资金净流入5174.91万元。（数据宝） | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 机构专用 | 8867.62 | | 国盛证券有限责任公司深圳粤海街道证券营业部 | 4746.58 | | 高盛(中国)证 ...

证券代码：300239 证券简称：东宝生物 公告编号：2025-049 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于 2024 年度权益分派实施后调整 回购股份价格上限和数量的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"公司")于 2025 年 1 月 3 日召 开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了《关于回购 公司股份方案的议案》。根据相关法律法规及《公司章程》规定，本次回购股份 方案无需提交公司股东大会审议。使用公司自有资金和/或自筹资金以集中竞价 交易方式或法律法规允许的方式回购部分公司已发行的人民币普通股(A 股)股票， 并在未来适宜时机将回购股份用于实施员工持股计划或股权激励。本次回购价格 不超过人民币 8.00 元/股(含)，本次回购股份的实施期限为公司董事会审议通过 回购股份方案之日起 12 个月内。按照回购股份价格上限人民币 8.00 元/股，回 购金额下限人民币 5,000 万元-上限人民币 10,000 万元(含)测算，预计回购股份 数 ...

关注创新药行情全面扩散下的投资机会 证 券 研 究 报 告 2025下半年医药生物行业投资策略 证券分析师：张静含 A0230522080004 2025.6.9 投资案件 一改颓势，医药板块上半年表现亮眼 -15% -10% -5% 0% 5% 10% 15% 20% 25% 2025/01/02 化学制药 生物制品 医疗器械 医药商业 中药 医疗服务 年初至今医药及大盘涨跌幅对比 年初至今医药二级板块涨跌幅对比 -10% -8% -6% -4% -2% 0% 2% 4% 6% 8% 10% 25/01 25/02 25/03 25/04 25/05 25/06 相对全A涨跌幅 医药生物(申万) 万得全A(除金融、石油石化) www.swsresearch.com 证券研究报告 2 ◼ 年初至6/5，医药生物（申万）指数年初至今累计涨跌幅为+8.0%，同期万得全A（除金融石油石化）涨跌幅为 +2.7%，相对大盘涨跌幅为+5.2%，在申万一级行业中排名第5。从二级行业行情表现来看，年初至今涨跌幅排名分 别为：化学制药（35.0x→41.6x）、生物制品（29.8x→41.6x）、医疗器械（30.3x→34.7 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Market Overview - On June 9, the A-share market saw all three major indices close higher, with the Shanghai Composite Index rising by 0.43% to 3399.77 points, the Shenzhen Component Index increasing by 0.65% to 10250.14 points, and the ChiNext Index up by 1.07% to 2061.29 points. The total trading volume in the Shanghai and Shenzhen markets reached 128.64 billion yuan, an increase of 13.44 billion yuan compared to the previous trading day [1]. Industry Performance - The pharmaceutical sector exhibited the strongest performance on June 9, with chemical pharmaceuticals reaching a nearly four-year high, immunotherapy hitting a two-year high, and weight-loss drugs achieving a one-and-a-half-year high. Other segments such as generic drugs and hepatitis treatments also reached new highs for the year [2]. - In May, at least six domestic innovative pharmaceutical companies announced business development (BD) transactions, primarily involving cross-border cooperation with foreign pharmaceutical companies. Additionally, at the recent ASCO conference, 73 research projects from China were selected for oral presentations, including 11 significant research abstracts [2]. Company Insights - Lingpai Technology, a notable stock on June 9, saw its share price increase by over 10%. The company specializes in the research, production, and sales of new environmentally friendly surface engineering chemicals. In Q1 2025, Lingpai reported an earnings per share of -0.15 yuan and a net profit attributable to shareholders of -26.63 million yuan, with a year-on-year growth rate of 14.54%. The company has completed the research and development of the NCM811 battery chemical system and is actively involved in the new energy vehicle, energy storage, and engineering machinery sectors [4].

Investment Rating - The investment rating for the company is "Buy" [7] Core Viewpoints - The report is optimistic about the commercialization prospects of the company's products, including the monoclonal antibody "Sai Li Qi" and the bispecific antibodies GR2002 and GR1803, anticipating data readouts that could enhance valuation [1] - The company achieved significant revenue growth in 2024, with total revenue reaching 30.10 million yuan, and a slight narrowing of net losses to 797 million yuan [1] - The company has a differentiated pipeline with key products progressing steadily, including the approval of Sai Li Qi for moderate to severe plaque psoriasis and ankylosing spondylitis [1][2] Financial Performance - In Q1 2025, the company reported revenue of 20.16 million yuan and a net loss of 121 million yuan, with R&D expenses at 10.30 million yuan [1] - Revenue projections for 2025-2027 are estimated at 199 million yuan, 533 million yuan, and 1.07 billion yuan respectively, reflecting a strong growth trajectory [4][6] - The company maintains high R&D expenditure, with 610 million yuan in 2024, indicating a commitment to innovation [1] Pipeline Development - The GR1802 monoclonal antibody is progressing through clinical trials for multiple indications, with significant market potential [2] - The GR1801 rabies virus antibody is currently under review for market approval, with promising commercial prospects [2] - Other pipeline products, including GR2001 and GR1803, are advancing through clinical stages and partnerships, demonstrating the company's innovative capabilities [3]

Group 1 - The demand for skilled talent in enterprises is diverse, requiring targeted services to supply urgently needed personnel [1] - Suzhou is accelerating the construction of an employment-friendly city, with 12 major projects signing cooperation agreements with labor service units [2][4] - In 2024, Suzhou will explore pre-employment labor services and initiate employment assessment for major projects to accurately evaluate their employment capacity [2] Group 2 - A total of 211 major projects with investments exceeding 300 million yuan have been included in the employment assessment, with a total investment of over 231.4 billion yuan [4] - The projects are expected to create 51,189 jobs, with 37,917 new hires needed [4] - The integration of production and education is emphasized as a key driver for innovation and development in Suzhou [5] Group 3 - Strategic cooperation agreements were signed between 10 quality universities and 10 leading enterprises in Suzhou to enhance collaboration in talent cultivation [5] - The establishment of a low-altitude economy education and skills ecosystem aims to accelerate the training of high-skilled talent [6] - Suzhou has organized over 400 school-enterprise matching activities, attracting more than 480,000 skilled talents [6][7] Group 4 - The city is enhancing the efficiency of government-school-enterprise collaboration to better serve the integration of education and industry [6] - A digital exchange platform for school-enterprise cooperation is being developed to centralize talent resource information and skill demands [7]

Market Overview - The Shanghai Composite Index rose by 0.23%, the Shenzhen Component Index increased by 0.58%, and the ChiNext Index gained 1.17% [1] - Over 3000 stocks declined, indicating a mixed market sentiment despite the activity in popular sectors [1] - The trading volume in both markets reached 1.29 trillion yuan, an increase of over 130 billion yuan compared to the previous trading day [1] Key Industry Developments - The first domestically produced nine-valent HPV vaccine, named Xinkening 9, has been approved for market release, expected to be priced at half the cost of Merck's version [2] - The popularity of the Scottish Premier League has surged, with average attendance exceeding 20,000 per match, surpassing the attendance of the Chinese Super League [2] - New consumer stocks in Hong Kong, including brands like Mixue and Laoputang, are experiencing collective adjustments, with significant sell-offs expected due to large unlocks [2] New Listings and Investment Opportunities - A new stock, Zhongce Rubber, listed today, saw a peak increase of over 20% during trading but closed with a gain of less than 7%, marking one of the lowest increases for new stocks this year [2] - Upcoming IPOs include Jiao Da Tie Fa, expected to list on June 10 with a projected increase of around 300% [2] - The China International Capital Corporation (CICC) is set to launch two REITs: the CICC Yizhuang Industrial Park REIT on June 10 and the CICC China Green Development Commercial REIT on June 13 [3][4] Fixed Income and Currency Insights - The current yield on ten-year government bonds is approximately 1.7%, with an expected range of 1.5% to 1.9%, while thirty-year bonds yield around 1.95% [9] - The offshore exchange rate is around 7.18, with key short-term levels identified between 7 and 7.5 [10]

Group 1 - Changan Automobile's indirect controlling shareholder will change to a newly established central enterprise after the separation of its automotive business from the Equipment Group, with no significant impact on the company's operations [1] - Zhifei Biological's 15-valent pneumococcal conjugate vaccine application for production registration has been accepted, which could enhance the company's market position and competitiveness [2] - Wanda Film is launching a shareholder return activity, allowing eligible shareholders to purchase movie ticket packages at a significantly reduced price [3] Group 2 - InSail Group plans to acquire 80% of the equity of Zhizhe Brand through a combination of issuing shares and cash payment [4] - Muyuan Foods reported May sales of 6.406 million pigs, with a revenue of 12.258 billion yuan, reflecting a year-on-year increase of 26.93% [6] - Shenzhou Cell plans to raise up to 900 million yuan through a private placement to supplement working capital [7] Group 3 - China Oil Engineering's subsidiary received a contract worth approximately 2.94 billion USD for a gas pipeline project in Iraq [8] - Dongfeng Motor reported a 31.26% year-on-year decrease in May sales of new energy vehicles, totaling 1,270 units [14] - Huazhong Pharmaceutical's subsidiary received a drug registration certificate for a new antidepressant, which has been in development since 2021 [24] Group 4 - Juhua Technology won a bid for a 197 million yuan project from the State Grid [27] - Zhaojin Mining announced plans to acquire a controlling stake in Zhixue Cloud, which may constitute a significant asset restructuring [26] - Mypo Medical intends to acquire 100% of Yijie Medical's equity, expanding its capabilities in the interventional field [13]